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Résumé en
anglais
Additional neurological features have recently been described in seven families
transmitting pathogenic mutations in OPA1, the most common cause of autosomal
dominant optic atrophy. However, the frequency of these syndromal ‘dominant optic
atrophy plus’ variants and the extent of neurological involvement have not been
established. In this large multi-centre study of 104 patients from 45 independent
families, including 60 new cases, we show that extra-ocular neurological
complications are common in OPA1 disease, and affect up to 20% of all mutational
carriers. Bilateral sensorineural deafness beginning in late childhood and early
adulthood was a prominent manifestation, followed by a combination of ataxia,
myopathy, peripheral neuropathy and progressive external ophthalmoplegia from the
third decade of life onwards. We also identified novel clinical presentations with
spastic paraparesis mimicking hereditary spastic paraplegia, and a multiple sclerosis-
like illness. In contrast to initial reports, multi-system neurological disease was
associated with all mutational subtypes, although there was an increased risk with
missense mutations [odds ratio = 3.06, 95% confidence interval = 1.44–6.49; P =
0.0027], and mutations located within the guanosine triphosphate-ase region (odds
ratio = 2.29, 95% confidence interval = 1.08–4.82; P = 0.0271). Histochemical and
molecular characterization of skeletal muscle biopsies revealed the presence of
cytochrome c oxidase-deficient fibres and multiple mitochondrial DNA deletions in
the majority of patients harbouring OPA1 mutations, even in those with isolated optic
nerve involvement. However, the cytochrome c oxidase-deficient load was over four
times higher in the dominant optic atrophy + group compared to the pure optic
neuropathy group, implicating a causal role for these secondary mitochondrial DNA
defects in disease pathophysiology. Individuals with dominant optic atrophy plus
phenotypes also had significantly worse visual outcomes, and careful surveillance is
therefore mandatory to optimize the detection and management of neurological
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